SG EZ-fill Platform

Thanks to the modularity, we can provide tailor-made solutions designed to deliver high-quality standards even when scaling-up. Our Pen Injector Assembly Line is an example of a flexible mid-high speed pen injector line assembling different formats and integrating extensive in-process controls.

Stevanato Group has launched SG Nexa 3x Cartridges, a full range of products that offer up to 3 times the mechanical resistance when compared to a standard glass container. Thanks to an external anti-friction and anti-scratches silicone coating, SG Nexa 3x better withstands the stresses of fill/f...

The continuing desire to reduce needlestick injuries led us to develop the SG EZ-fill Integrated Safety System. This groundbreaking, fully passive needle shield comes ready to fill and requires no additional assembly steps. SG ISS is both easy to use and intuitive to handle. Activating the automatic s...

The Integrated Tip Cap has been developed to be the ideal match for SG EZ-fill® luer lock cone syringes with its twist-off closure system. The Integrated Tip Cap comprises of a rubber component inserted in a rigid plastic cap, screwed onto a luer lock adaptor and then pre-assembled on the SG EZ-f...

We present a modular, robotic, proof-of-concept system for inspecting parenterals. By employing artificial intelligence principles and applying the technology to the inspection task, we engineered the Vision Robot Unit (VRU).
The VRU is a reliable, autonomous island machine, capable o...

Our analytical testing facilities focus on investigating physico-chemical properties of primary packaging materials and components and studying the interactions between container closure system and drugs.  • Our Italy based laboratory, SG Lab Analytics, works in compliance with ISO/IEC 17025: 2018 and...

SG Alba is a turning point in the development of parenteral primary packaging, representing the best-in-class solution for biologics. The reduced variability of materials in contact with the drug throughout its lifecycle makes our SG Alba platform the perfect solution for de-risking the developme...

Owen Mumford's device expertise is joining forces with Stevanato Group's unique engineering and manufacturing experience. The collaboration brings the full value of the Aidaptus® auto-injector platform to the market, helping patients self-administer their therapy using a simple and easy-to-use device.Aidap...

Leveraging our market-leading EZ-fill® technology, we developed EZ-fill Smart™: an enhanced version of our pre-sterilized platform aiming to make RTU vials a standard, ultimately increasing patient safety. With EZ-fill Smart™ we provide you with a highly standardized platform, featuring increased qual...

Stevanato Group’s On-Body Delivery System (OBDS) is a semi-reusable drug delivery device composed of a disposable pod with a pre-loaded cartridge and a reusable controller. With the ability to deliver micro-precision basal doses and full-content bolus injections, the OBDS is a highly flexible, customizable...

SG Alina is a user-friendly disposable pen injector based on proven technology. The variable-dose pen injector is under development at Stevanato Group in collaboration with Cambridge Design Partnership. It is based on Axis-D intellectual property exclusively licensed from pen injector d...

Tremendous growth opportunities exist for auto-injectors as their value is increasingly being recognised across several therapy areas, experts have told a recent CPHI webinar, sponsored by Stevanato Group.

Stevanato Group has launched SG Nexa 3x Cartridges, a full range of products that offer up to 3 times the mechanical resistance when compared to a standard glass container.
Thanks to an external anti-friction and anti-scratches silicone coating, SG Nexa 3x better withstands the stresses of fill/finish processes too.

Watch this recent webinar exploring the challenges of distributing COVID-19 vaccines to a global population and the role the packaging sector is playing to ensure safe and speedy distribution of shots

SG Alina is a variable-dose and fixed-dose and pen injector offered by Stevanato Group in collaboration with Cambridge Design Partnership.
It is based on Axis-D intellectual property and technology exclusively licensed from pen injector device expert Haselmeier, for the treatment of diabetes.

The increasing number of complex and sensitive biologics and the administration shift from hospitals to patients' homes are two of today’s main biopharmaceutical industry challenges. Complex drugs and self-administration require an appropriate primary packaging selection from the beginning of the bio drug development process. In this article, you will learn how Stevanato Group can support biopharma companies in the container closure system choice leveraging its 70-year expertise in glass primary packaging, up to the integration into drug delivery systems, backed up by solid characterization analysis.

Stevanato Group

Lars Keinicke Hansen, Chiara Mussoi, and Odra Pinato, all of Stevanato Group, describe how the streamlining of processes and harmonisation of products and services can better serve pharmaceutical companies. A case study highlights how a unique combination of expertise in automation and glass primary packaging benefited pharma giant Merck Serono in a recent project.

SG ITC (Integrated Tip Cap), the twist-off closure of Stevanato Group, is an established and especially user-friendly system solution for Luer Lock syringes, which will now be included in Gerresheimer program.

Assembly Equipment combining transport platforms and process modules: an offer of manual, semi-automatic or fully automatic assembly lines customized to your device program.

Patients suffering from chronic and acute pain disorders will benefit from a convenient, discreet, and easy-to-use device delivering a novel alternative to opioid-based pain management.

A flexible mid-high speed pen injector line assembling different formats and integrating extensive in-process controls.

This recent webinar sponsored by Stevanato Group focuses on early considerations for emergency use auto-injector development and manufacturing.

Presenting a case study on Stevanato’s Maverick, Adam Stops, Drug Delivery Systems Product Manager at Stevanato Group explained that the emergency use auto-injector is the result of a successful partnership with Duoject Medical Systems.

“We have partnered with Duoject to provide a market-leading device for our customers in the emergency use space. Along with Novocol, Duoject’s parent company, if requested, we can provide end-to-end services: the device, device manufacturing, fill/finish, and final device assembly. This is truly an end-to-end solution,” he said.

Watch the webinar to hear more from Adam and other experts from Duoject Medical Systems and IQVIA.

The COVID-19 pandemic has placed a spotlight on the readiness and requirements of pharma packaging companies to support the distribution and delivery of a potential vaccine and selecting the most suitable primary packaging options for drug products is one of the most crucial considerations in the drug development process, according to industry experts speaking in this CPHI China Virtual Expo Connect Webinar, sponsored by Stevanato Group. Daniel Martinez, Product Manager, Stevanato Group pointed out that speed to market is a primary consideration for vaccine developers, particularly in the current pandemic environment, and keeping the same type of container is essential to reaching this target. “The advantage of using a vial is that it is a pretty versatile container – it’s good for liquids, it’s good for lyophilized products, powders and cryogenic,” he told the audience, noting that some of the COVID-19 vaccines being developed need to be stored at -70 degrees. Watch the webinar to hear more from Daniel and experts from NRL Enterprise Solutions & IQVIA.

Stevanato Group and Duoject Medical Systems are developing a reliable and user-friendly auto-injector for emergency use, suitable for an effective and fast intramuscular injection.
The device features an intuitive activation, while the needle is never exposed and automatically retracted after injection.

Advances in auto-injector design now provide the option to use both 1ml and 2.25mL syringes plus employ technology to adapt to varying fill volumes and viscosities all whilst maintaining the same device form. This provides a solution for the formulation changes that take place during drug development, clinical trials, and life cycle management. When looking at the performance of any parenteral injection device, the drug containment systems play a crucial role. Auto-injector performance and functionality is strictly linked to key dimensional tolerances of glass syringes. We will illustrate the importance of syringe design to ensure these requirements and how monitoring dimensional parameters at an early stage of the development is key to ensure the intended use and ultimately work to preserve patients’ safety. Benefits of tight collaboration between device designer and manufacturer will also be discussed.